Delving into the Latest Updates on Vonoprazan Fumarate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

VONOPION, Vonoprazan, Vonoprazan fumarate (JAN/USAN)

+ [15]

Target

H+/K+ ATPase

Action

blockers

Mechanism

H+/K+ ATPase blockers(Potassium-transporting ATPase blockers)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersMouth and Tooth Diseases+ [4]

Active Indication

Non-erosive gastro-esophageal reflux diseaseErosive esophagitisHeartburn+ [10]

Inactive Indication

Non-erosive reflux disease

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Takeda Pharmaceutical Co., Ltd.

Zhejiang Jianfeng Pharmaceutical Co., Ltd.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

+ [4]

Inactive Organization

Hanlim Pharm Co., Ltd.

Sunshine Lake Pharma Co., Ltd.

License Organization

Takeda Pharmaceutical Co., Ltd.

Phathom Pharmaceuticals, Inc.

Lupin Ltd

+ [3]

Drug Highest PhaseApproved

First Approval Date

Japan (26 Dec 2014),

Duodenal UlcerEsophagitis, PepticHelicobacter pylori infection+ [1]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H20FN3O6S

InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N

CAS Registry881681-01-2

The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.
The main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.
Researchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.
Participants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.
Four weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.
Drug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.
Participants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.

Start Date15 Apr 2026

Sponsor / Collaborator

Bangabandhu Sheikh Mujib Medical University

ChiCTR2600122517

/ Not yet recruitingPhase 4IIT

Efficacy and Safety of Minocycline-Vonoprazan Dual Therapy Versus Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Multicenter, Open-Label, Randomized, Non-Inferiority Study

Start Date01 Apr 2026

Sponsor / Collaborator

The First Affiliated Hospital of Nanchang University

100 Clinical Results associated with Vonoprazan Fumarate

Login to view more data

100 Translational Medicine associated with Vonoprazan Fumarate

Login to view more data

100 Patents (Medical) associated with Vonoprazan Fumarate

Login to view more data

835

Literatures (Medical) associated with Vonoprazan Fumarate

01 May 2026·LIFE SCIENCES

Vonoprazan mitigates diethyl nitrosamine-induced acute liver injury in mice via modulating p-AMPK/ SIRT1/ PGC-1α and Keap1/Nrf2/HO-1 pathways

Article

Author: Al-Rasheedi, Zaid F ; El-Kashef, Dalia H ; Nour, Omnia A

BACKGROUND:

Vonoprazan (VON), a potassium-competitive acid blocker, is used in the treatment of acid-related disorders including GERD, gastritis, and esophagitis besides H. pylori infection.

AIM:

This study was carried out to elucidate the hepatoprotective effect of VON against diethylnitrosamine (DN)-induced acute liver injury (ALI) in mice.

METHOD:

Thirty-six male mice were randomly alienated into six groups, including control group, VON20 group, DN-induced ALI group, VON5 + DN group, VON10 + DN group and VON20 + DN group. ALI was induced in mice using DN (150 mg/kg, i.p.). VON was orally administered at three doses (5, 10 and 20 mg/kg) for 7 days before DN injection, and DN was injected on day 7.

RESULTS:

In comparison to DN group, VON exerted hepatoprotective effect, evidenced by significant decrease in serum levels of ALT, AST, GGT and LDH. Additionally, VON administration restored oxidant/anti-oxidant balance, as presented by significant decrease in hepatic levels of MDA in addition to profound increase in hepatic level of GSH and TAC. Furthermore, VON administration attenuated DN-induced reduction in hepatic levels of p-AMPK, SIRT1, PGC-1α, Nrf2 and HO-1. VON also induced significant reduction in hepatic levels of Keap1, NF-κB and TNF-α when compared to DN. Histopathologically, VON mitigated DN-induced histopathological irregularities in hepatic tissues.

CONCLUSION:

VON suggests hepatoprotective potential, in a dose dependent manner, possibly due to their antioxidant and anti-inflammatory properties.

01 Apr 2026·DEN open

A Case of Gastric Neuroendocrine Tumor With a Raspberry‐Like Appearance on the Background of Acid‐Suppressive Therapy‐Related Gastropathy

Article

Author: Arakawa, Takeo ; Noma, Eriko ; Funabiki, Toshihiro ; Goto, Osamu ; Moriguchi, Yoshiaki ; Iseki, Mari ; Oka, Yasuhiro ; Nakahodo, Jun ; Iizuka, Toshiro ; Horiguchi, Shin‐ichiro

ABSTRACT:

We report the case of a 52‐year old man who was referred to our institution after a routine health check identified an asymptomatic gastric polyp. The medical history of the patient included reflux esophagitis, for which he had been treated with vonoprazan 10 mg daily for 6 years after initially receiving proton pump inhibitors. Endoscopy revealed a 4‐mm, hemispherical, uniformly reddish Yamada type II lesion on the anterior wall of the gastric body, arising from nonatrophic mucosa with multiple small hyperplastic polyps. Magnifying narrow‐band imaging revealed a regular microvascular and microsurface pattern, producing a raspberry‐like appearance. Histological examination of the biopsy specimen revealed a grade 1 neuroendocrine tumor. Contrast‐enhanced computed tomography revealed no evidence of metastatic lesions. En bloc resection was successfully performed using endoscopic submucosal dissection. Pathological examination confirmed a 5‐mm grade 1 neuroendocrine tumor with negative margins and no vascular invasion. Gastric neuroendocrine tumors with raspberry‐like morphology are rare. This case underscores the importance of considering gastric neuroendocrine tumors in the differential diagnosis of raspberry‐like gastric lesions, particularly in patients with potent acid‐suppressive therapy–related gastropathy.Trial Registration : N/A.

01 Mar 2026·HELICOBACTER

Efficacy and Safety of Vonoprazan‐Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial

Article

Author: Li, Ji ; Zhang, Jin‐Yan ; Huang, Yu‐Lin ; Lei, Xiao‐Yi ; Xu, Gui‐Hua ; Huang, Wei‐Feng ; Xu, Dong

ABSTRACT:

Background:

Vonoprazan (VPZ), a potassium‐competitive acid blocker, has shown promising efficacy in Helicobacter pylori ( H. pylori ) eradication. However, direct comparisons of VPZ‐based dual therapy (V‐DT), triple therapy (V‐TT), and bismuth quadruple therapy (V‐BQT) remain limited. This study aimed to evaluate and compare the efficacy, safety, and compliance of these three regimens as first‐line treatments for H. pylori infection.

Methods:

375 adults were randomized (1:1:1) to receive V‐DT (VPZ 20 mg bid + amoxicillin 1 g tid for 10 days), V‐TT (VPZ 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid for 14 days), or V‐BQT (VPZ 20 mg bid + amoxicillin 1 g bid + clarithromycin 500 mg bid + bismuth 240 mg bid for 10 days). The primary outcome was H. pylori eradication rate by intention‐to‐treat (ITT), modified ITT (mITT), and per‐protocol (PP) analyses. Secondary outcomes included adverse events and compliance.

Results:

Eradication rates were 92.0% (95% confidence interval [CI]: 85.8%–96.1%), 89.6% (95% CI: 82.9%–94.3%), and 88.8% (95% CI: 81.9%–93.7%) in ITT; 94.3% (95% CI: 88.5%–97.7%), 94.9% (95% CI: 89.3%–98.1%), and 94.1% (95% CI: 88.2%–97.6%) in mITT; and 94.2% (95% CI: 88.4%–97.6%), 95.6% (95% CI: 90.0%–98.5%), and 94.8% (95% CI: 89.0%–98.1%) in PP analyses for V‐DT, V‐TT, and V‐BQT, respectively. The efficacy of V‐DT and V‐TT was noninferior to that of V‐BQT. Adverse events were significantly lower with V‐DT (6.4%) than with V‐TT (36.0%) and V‐BQT (49.6%) ( p < 0.001). Compliance exceeded 93% in all groups, with no significant differences ( p = 0.250).

Conclusions:

All three regimens achieved high eradication rates, with V‐DT and V‐TT being statistically noninferior to V‐BQT. The 10‐day V‐DT regimen achieved eradication rates comparable to V‐BQT with substantially fewer adverse events and reduced antibiotic use, supporting its potential as a simplified first‐line option for H. pylori eradication.

Trial Registration:

Chinese Clinical Trial Registration Number: ChiCTR2300072857

131

News (Medical) associated with Vonoprazan Fumarate

20 Apr 2026

·www.biospace.com

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at . A recording will be available for 90 days following the conclusion of the call. About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA ® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at and follow on LinkedIn and X . MEDIA CONTACT Nick Benedetto 1-877-742-8466 media@phathompharma.com INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

License out/inDrug ApprovalFinancial Statement

06 Apr 2026

·www.globenewswire.com

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NYDate: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDTManagement to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

License out/in

06 Apr 2026

·www.biospace.com

Phathom Pharmaceuticals to Participate in Upcoming April 2026 Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NY Date: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 15, 2026 Fireside Chat: 1:30 pm EDT Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at . Recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA ® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at and follow on LinkedIn and X . MEDIA CONTACT Nick Benedetto 1-877-742-8466 media@phathompharma.com INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

License out/inDrug Approval

100 Deals associated with Vonoprazan Fumarate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10466	Vonoprazan Fumarate	A02BC08	DB11739

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Non-erosive gastro-esophageal reflux disease	United States	Phathom Pharmaceuticals, Inc.	17 Jul 2024
Erosive esophagitis	United States	Phathom Pharmaceuticals, Inc.	01 Nov 2023
Heartburn	United States	Phathom Pharmaceuticals, Inc.	01 Nov 2023
Erosive gastro-esophageal reflux disease	South Korea	Takeda Pharmaceuticals Korea Co., Ltd.	29 Mar 2019
Duodenal Ulcer	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014
Esophagitis, Peptic	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014
Helicobacter pylori infection	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014
Stomach Ulcer	Japan	Takeda Pharmaceutical Co., Ltd.	26 Dec 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peptic Ulcer Hemorrhage	NDA/BLA	China	YiChang HEC ChangJiang Pharmaceutical Co., Ltd.	08 Apr 2026
Non-erosive reflux disease	Phase 3	United States	Phathom Pharmaceuticals, Inc.	17 Jan 2022
Eosinophilic Esophagitis	Phase 2	United States	Phathom Pharmaceuticals, Inc.	30 Oct 2025
Gastroesophageal Reflux	Phase 2	Belgium	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Bulgaria	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Czechia	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Estonia	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	Poland	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Gastroesophageal Reflux	Phase 2	United Kingdom	Takeda Pharmaceutical Co., Ltd.	14 Jul 2016
Dyspepsia	Phase 1	China	Zhejiang Jianfeng Pharmaceutical Co., Ltd.	17 May 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06831344 (CTgov)	Phase 1	-	25	Vonoprazan (Treatment A: Vonoprazan 10 mg)	povigxstrr(divflmxflj) = zxectiihvr lowcufmchf (wiixblxuje, 47.8) View more	-	19 Dec 2025
				Vonoprazan (Treatment B: Vonoprazan 10 mg)	povigxstrr(divflmxflj) = nibvxpfyda lowcufmchf (wiixblxuje, 41.4) View more
NCT04198363 (Pubmed \| Chin Med J (Engl))	Phase 3	Helicobacter pylori infection	510	Vonoprazan-based quadruple therapy	disgmwacyh(jkhmhrhioq) = sbglgzsziw wcpnzuyevm (yotscwbjlc )	Positive	20 Nov 2025
				Esomeprazole-based quadruple therapy	disgmwacyh(jkhmhrhioq) = jwzaoubgvr wcpnzuyevm (yotscwbjlc )
NCT05195528 (Pubmed \| Am J Gastroenterol)	Phase 3	Non-erosive reflux disease	772	Placebo	rgkptddbaw(vdspnsxwlh) = ktljypprvx mysjdkpuac (wiznkzbspb )	Positive	13 Oct 2025
				Vonoprazan 10 mg	rgkptddbaw(vdspnsxwlh) = jfnohhasbr mysjdkpuac (wiznkzbspb )
NCT06811207 (Pubmed \| Ther Adv Gastroenterol)	Phase 4	Helicobacter pylori infection First line	121	vonoprazan+amoxicillin	xilwrssces(epzjyafxvm) = xvnualzndl pzioyyeouz (pthzqzksfw ) View more	Similar	01 Sep 2025
				esomeprazole+amoxicillin	xilwrssces(epzjyafxvm) = fguhfpommq pzioyyeouz (pthzqzksfw ) View more
NCT06162949 (VONTAPE, Pubmed \| Helicobacter)	Phase 4	Helicobacter pylori infection	242	Vonoprazan-Based Triple Therapy	kvzilddssu(ssmzofkhkx) = monrjnnpyp fptxaponmj (ifnzwjiorr ) View more	Positive	01 Sep 2025
				Esomeprazole-Based Triple Therapy	kvzilddssu(ssmzofkhkx) = bwtlywkjus fptxaponmj (ifnzwjiorr ) View more
NCT06168084 (not provided, Pubmed \| United European Gastroenterol J)	Phase 4	Helicobacter pylori infection	688	Vonoprazan and High-Dose Amoxicillin (VHA) dual therapy	cwcbbaujuk(ddnopfywhp) = The overall AE incidence in the VHA group was significantly lower compared with that in the TFEB group (13.4% vs.. 28.5%, p < 0.001) noaedcgozh (dyfyevaouo )	Positive	21 Jun 2025
				Tetracycline- and Furazolidone-based Bismuth-Containing Quadruple Therapy (TFEB)
NCT05191888 (Pubmed \| Am J Gastroenterol)	Phase 3	Helicobacter pylori infection First line	906	Vonoprazan high-dose dual therapy	tvjmjqobje(ngczkbvnwl) = ikxzjjdrds zebbnivnjt (vxtzvjolyn ) View more	Positive	16 Jun 2025
				Vonoprazan triple therapy	tvjmjqobje(ngczkbvnwl) = jkbiuuwxhd zebbnivnjt (vxtzvjolyn ) View more
NCT05649540 (Pubmed \| Helicobacter)	Phase 4	Helicobacter pylori infection	900	High-dose amoxicillin (HVA)	xwnpgkxhjv(gsdticjsxi) = hyodfohzvw tnruukjvhx (ngmniqandt )	Positive	01 May 2025
				Medium-dose amoxicillin (MVA)	xwnpgkxhjv(gsdticjsxi) = whnaxlipnb tnruukjvhx (ngmniqandt )
NCT06391177 (CTgov)	Phase 1	Erosive esophagitis \| Helicobacter pylori infection \| Gastroesophageal Reflux ... View more	15	Vonoprazan (Vonoprazan 20 mg QD)	lolbpmwefw(hfpwbtaduh) = ndhychnfju xnattytdcg (nwswimqtgv, 61.3) View more	-	25 Mar 2025
				Vonoprazan (Vonoprazan 20 mg BID)	lolbpmwefw(hfpwbtaduh) = erjrnlvrzb xnattytdcg (nwswimqtgv, 107) View more
NCT05469685 (Pubmed \| Front Pharmacol)	Phase 4	Helicobacter pylori infection	914	10-day vonoprazan-amoxicillin (VA) therapy	cpduiswbzg(fsehnnajia) = ghttxgnzsb fspyefvkqm (byvjplqhzy ) View more	Positive	24 Mar 2025
				14-day vonoprazan-amoxicillin (VA) therapy	cpduiswbzg(fsehnnajia) = nfxahcgoua fspyefvkqm (byvjplqhzy ) View more